SCHEMBL13633920

SCHEMBL13633920

CSc1nccc(-c2ccc(S(=O)(=O)Nc3cccc4ncccc34)s2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.62
LMNA P02545 2/20 0.62
TP53 P04637 2/20 0.62
ALOX15 P16050 2/20 0.62
NPSR1 Q6W5P4 2/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
S1PR4 O95977 1/20 0.62
ALDH1A1 P00352 1/20 0.62
PKM P14618 1/20 0.62
HPGD P15428 1/20 0.62
S1PR1 P21453 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
GABRA1 P14867 1/20 0.59
PFKFB3 Q16875 2/20 0.58
PFKFB4 Q16877 1/20 0.53
TDP1 Q9NUW8 2/20 0.53
TSHR P16473 1/20 0.53
OPRK1 P41145 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633864 0.89 GABRA1 (0.62) HTTLMNATP53ALOX15NPSR1
SCHEMBL3817307 0.86 GABRA1 (0.61) HTTLMNAALOX15NPSR1MEN1
SCHEMBL13633847 0.82 GABRA1 (0.55) HTTLMNATP53ALOX15NPSR1
SCHEMBL13633765 0.82 GABRA1 (0.56) HTTLMNATP53ALOX15NPSR1
SCHEMBL13211036 0.77 GABRA1 (0.69) LMNANPSR1ALDH1A1PKMHPGD
SCHEMBL13633846 0.76 SLC40A1 (0.58) LMNATP53NPSR1MEN1KMT2A
SCHEMBL13633912 0.76 GABRA1 (0.59) MEN1KMT2AGABRA1PFKFB3PFKFB4
SCHEMBL13633919 0.74 GABRA1 (0.72) HTTLMNANPSR1MEN1KMT2A
SCHEMBL6627698 0.74 GABRA1 (0.65) HTTLMNAMEN1KMT2AGABRA1
SCHEMBL788220 0.73 PFKFB3 (1.00) TP53GABRA1PFKFB3PFKFB4CCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A HTT 2971/4885LMNA 2349/4885TP53 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.